The group indicated it had obtained orphan drug status for Zeneo® Midazolam from the FDA for the treatment of “status epilepticus”, i.e. epileptic crises of over five minutes.
03 Feb 2018
Orphan disease status for Zeneo® Midazolam in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Orphan disease status for Zeneo® Midazolam in the US
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
03 Feb 2018 -
Author:
Fabrice Farigoule -
Pages:
2
The group indicated it had obtained orphan drug status for Zeneo® Midazolam from the FDA for the treatment of “status epilepticus”, i.e. epileptic crises of over five minutes.